ADIL
Adial Pharmaceuticals, Inc. [ADIL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ADIL Stock Summary
Top 10 Correlated ETFs
ADIL
Top 10 Correlated Stocks
ADIL
In the News
ADIL Financial details
Company Rating
-
Market Cap
9.45M
Income
-5.11M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.33
Forward P/E
-
PEG
0.03
P/S
-
P/B
0.86
P/C
-
P/FCF
-0.28
Quick Ratio
1.26
Current Ratio
2.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-6.45
EPS next Y
-
EPS next Q
-
EPS this Y
-98.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-2.54%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-211%
ROE
-233%
ROC
-3.85%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.77-14.0
52W High
-
52W Low
-
RSI
27
Rel Volume
0.02
Avg Volume
6.43M
Volume
115.15K
Perf Week
-17.93%
Perf Month
-25.72%
Perf Quarter
-19.97%
Perf Half Y
-17.95%
-
-
-
-
Beta
1.527
-
-
Volatility
0.03%, 0.09%
Prev Close
0%
Price
0.7799
Change
-3.12%
Company Profile
- Volume Average 6.43M
- Market Capitalization 9.45M
- Employee 4
- CEO Mr. Cary John Claiborne MBA
- Headquarters Charlottesville,VA,US
- IPO Date 2018-07-27
-
Website
https://www.adialpharma.com 
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
